Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment

doi:10.3748/wjg.v9.i12.2695

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 12

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2539)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-3) series.

Item

Count

PDF

263

HTML

2153

Tables (1-3)

123

Sum=2539

Dec 15, 2003 (publication date) through May 6, 2024

Times Cited of This Article

Times Cited (43)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Viral Hepatitis

World J Gastroenterol. Dec 15, 2003; 9(12): 2695-2697
Published online Dec 15, 2003. doi: 10.3748/wjg.v9.i12.2695

Table 3 Comparison of HBeAg seroconversion among patients infected by genotype B and C HBV

HBeAg seroconversion	Genotype B	Genotype C	P value 1	P value 2
Control	10/29 (35%)	14/67 (21%)	0.25	0.41
Lamivudine	2/14 (14%)	2/21 (10%)	1.00	0.51

P value 1: unadjusted comparison of genotype B versus geno-type C; P value 2: comparison of genotype B versus genotype C after adjustment for age, gender, initial ALT levels and fol-low-up duration.

Citation: Chan HLY, Wong ML, Hui AY, Chim AML, Tse AML, Hung LCT, Chan FKL, Sung JJY. Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. World J Gastroenterol 2003; 9(12): 2695-2697
URL: https://www.wjgnet.com/1007-9327/full/v9/i12/2695.htm
DOI: https://dx.doi.org/10.3748/wjg.v9.i12.2695